Mbx Biosciences, Inc. (MBX) Stock Price & Analysis
Mbx Biosciences, Inc. (MBX) rose 3.00% to USD 29.87 as of June 10, 2026 at 03:14 UTC, according to Nexqual real-time market data.
MBX last closed at USD 29; the session ranged USD 28.35–30.56 on volume of 296,000 shares. Market capitalization is $1.42B, with a 52-week range of USD 9.43–45.85 (NMS). Source: Nexqual, June 10, 2026 at 03:14 UTC.
Key Statistics (as of June 10, 2026 at 03:14 UTC)
| Price | USD 29.87 |
|---|---|
| Change | ▲ 3.00% (up) |
| Previous Close | USD 29 |
| Open | USD 29.67 |
| Day Range | USD 28.35 – 30.56 |
| 52-Week Range | USD 9.43 – 45.85 |
| Volume | 296,000 shares |
| Market Cap | $1.42B |
| Exchange | NMS |
Technical Analysis (MBX)
Nexqual's technical model rates MBX "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:14 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.35 (neutral) |
| vs SMA50 | Below (USD 32.09) |
| MACD | -0.76 (negative) |
Analyst Ratings (MBX)
Wall Street analysts rate MBX "Strong Buy" based on 11 analysts, with a mean price target of USD 69.09 (range USD 20–91), per Nexqual as of June 10, 2026 at 03:14 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 69.09 |
| High Target | USD 91 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 11 / 0 / 1 |
Earnings (MBX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.6 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.51 vs est -0.58 ▲ beat |
| 2025-12-31 | USD -0.49 vs est -0.6 ▲ beat |
| 2025-09-30 | USD -0.63 vs est -0.68 ▲ beat |
| 2025-06-30 | USD -0.58 vs est -0.76 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:14 UTC.
Financials & Fundamentals (MBX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -25.73% |
| Debt / Equity | 0.13 |
| Current Ratio | 30.79 |
| Total Cash | $439.98M |
| Total Debt | $555,000 |
| Free Cash Flow | $-52.45M |
Source: Nexqual, June 10, 2026 at 03:14 UTC.
Financial Health Score (MBX)
Nexqual rates Mbx Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:14 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $440M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$77M |
| Efficiency | Critical — ROE -26%, ROA -17.7% |
Ownership (MBX)
| Insider Ownership | +2.70% |
|---|---|
| Institutional Ownership | +111.46% |
| Shares Outstanding | 47.60M |
| Float | 29.55M |
| Short % of Float | +14.18% |
Source: Nexqual, June 10, 2026 at 03:14 UTC.
Leadership (MBX)
Mbx Biosciences, Inc. is led by Peter Kent Hawryluk (age 56), CEO, President & Director, per Nexqual as of June 10, 2026 at 03:14 UTC.
| CEO, President & Director | Peter Kent Hawryluk (age 56) |
|---|---|
| Interim Chief Financial Officer | John W. Smither (age 72) |
| Senior Vice President of Investor Relations & Corporate Communications | Pete De Spain |
| Sr. Vice President of Discovery & Non-Clinical Development | Michael A. Dorato DABT |
| Senior Vice President of Regulatory & Quality | Mark Hope |
Major Backers & Investors (MBX)
Notable institutional backers of Mbx Biosciences, Inc. include Frazier Life Sciences Management, L.P. , Orbimed Advisors LLC., NEA Management Company, LLC, according to Nexqual as of June 10, 2026 at 03:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 13.98% |
| Orbimed Advisors LLC. | 7.64% |
| NEA Management Company, LLC | 7.59% |
| Wellington Management | 6.71% |
| FMR, LLC | 6.17% |
| Deep Track Capital, Lp | 5.79% |
| NVP Associates, LLC | 4.49% |
| Fidelity | 4.08% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.29% |
Source: Nexqual, June 10, 2026 at 03:14 UTC.
From Mbx Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
- Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
- The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
- In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | USD 20.56 | ▲ 2.8% |
| RAPP | Rapport Therapeutics, Inc. | USD 35.84 | ▼ 0.72% |
| ZBIO | Zenas BioPharma, Inc. | USD 18.42 | ▲ 5.44% |
| ALMS | Alumis Inc. | USD 20.01 | ▲ 4.98% |
| UPB | Upstream Bio, Inc. | USD 6.69 | ▼ 5.11% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:14 UTC. This page is informational and not investment advice.